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Highlights 
 In a multicentre study, the antibiotic susceptibility of 400 Bacteroides isolates were tested 
for 10 antibiotics. 
 Six MDR strains were found and their antibiotic resistance genes were investigated by 
molecular methods. 
 In this study we demonstrated the relatively large number of MDR strains within a 
comprehensive multicenter survey from one clinical centre. 
 We emphasized the importance of antimicrobial susceptibility testing and surveillance 
among B. fragilis group isolates. 
 
Abstract 
Introduction: Members of the Bacteroides fragilis group are the most important components 
of the normal human gut microbiota, but these bacteria can cause severe infections as well. 
Due to the frequent usage of antibiotics, the spreading of the MDR strains is a real threat 
worldwide.  
Materials and methods: In a multicentre study 400 Bacteroides isolates from five 
Hungarian microbiological laboratories were cultured and identified by MALDI TOF-MS. 
The MIC values of ten antibiotics were determined by the agar dilution method and evaluated 
by the breakpoints of EUCAST or CLSI.  
Results: We found six MDR strains, and their antibiotic resistance genes were investigated 
by molecular methods.The DNA amplicon of B. fragilis SZ38 strain was sequenced to look 
for a mutation in the gyrA gene. Among the six MDR isolates we found one cfiA-, two cepA, 
three cfxA-, two ermG-, six tetQ- three tetX- and two bexA-positive strains. None of them 
harboured cepA, nim, ermB and tetX1 genes. 
Discussion: In the past 12 years only a few cases of MDR Bacteroides infections have been 
published. Within a comprehensive multicenter survey we demonstrated the relatively large 
prevalence of MDR strains isolated in one centre with five isolates and one from another 
centre during a relatively short period of time. This study focused on the importance of 
antimicrobial susceptibility testing and surveillance among B. fragilis group isolates.  
 
Keywords: MDR Bacteroides isolates, antibiotic resistance genes, agar dilution, sequencing, 
RT-PCR 
 
1  Introduction 
Although the Bacteroides species are members of the normal human gut microbiota, 
these bacteria are significant opportunistic pathogens as well and are responsible for 
significant mortality, especially in the case of bacteremia [1,2]. B. fragilis can cause 
intraabdominal, skin and soft tissue infections and diarrhoea caused by enterotoxin producing 
B. fragilis isolates, particularly in young children under the age of five years [1,3]. The most 
important antibiotics against anaerobes are cephamycins, β-lactam/ β-lactamase inhibitors, 
carbapenems, metronidazole, clindamycin and fourth generation fluoroquinolones [1]. Nagy 
et al. reported a high rate of cefoxitin, clindamycin and moxifloxacin resistant strains, but 
amoxicillin/clavulanic acid, piperacillin/tazobactam, carbapenems and metronidazole are still 
very active antibiotics against B. fragilis group strains [4]. Antibiotic resistance is mediated 
by chromosomal genes or extrachromosomal plasmids, transferred by different types of 
transposons; and some genes require insertion sequence (IS) elements upstream of the gene 
for expression. Resistance to β-lactams is mediated mostly by chromosomal β-lactamase, 
encoded by cepA or cfxA genes, while carbapenem resistance is associated with cfiA gene by 
the expression of metallo-β-lactamase [5]. Although the mechanism of metronidazole 
resistance is not yet fully elucidated, the nim genes (nimA-H, nimJ) are thought to be 
responsible for it [6]. Ribosomal protection protein encoded by tetQ gene and enzymatic 
modification of the tetracycline molecule (tetX, tetX1) can cause tetracycline resistance [5,7]. 
Also, Macrolide-Lincosamide-Streptogramin B resistant determinants, erm(A-F, H) are 
widely distributed among Bacteroides species [5]. Mutations of the Quinolone Resistance-
Determining Region (QRDR) of the genes of gyrase (gyrA, gyrB) and/or topoisomerase IV 
(parC, parE), besides increased efflux, as in the Multi-Antimicrobial Extrusion protein 
(MATE-family, encoded by the bexA gene) may develope fluoroquinolone resistance [5,8]. In 
a recent Hungarian antibiotic resistance survey we tested six MDR Bacteroides isolates. 
 
2 Methods 
 2.1. Bacterial strains and cultivation  
 
In our study, 400 Bacteroides isolates collected from clinically relevant samples by five 
Hungarian clinical microbiological centres between January 2014 and  March 2016 were 
investigated. The strains were stored at -80 °C in Brain Heart Infusion (BHI) broth with 20% 
glycerol and cultured on Schaedler agar (bioMérieux, Fr.) for 48 hours, at 37 °C in an 
anaerobic chamber (Perkin Elmer, UK) under anaerobic conditions (85% N2, 10% CO2, 5% 
H2). The strains were identified with Matrix-Assisted Laser Desorption/Ionization Time-of-
Flight Mass Spectrometry (MALDI-TOF MS, Bruker Biotyper, Germany) and a Biotyper 
Version 3.0 software package was used and the isolates yielded a high confidence species 
level identification. The B. fragilis strains were identified as genetic Division II (exclusively 
positive for the cfiA carbapenemase gene) and Division I by the MALDI-TOF MS 
identification scheme published previously [9]. 
  2.2. Agardilution method 
 
The Minimal Inhibitory Concentration (MIC) values of 10 antibiotics (ampicillin, 
amoxicillin/clavulanic acid, cefoxitin, meropenem, clindamycin, moxifloxacin, 
metronidazole, tetracycline, tigecycline, chloramphenicol) of all the strains were determined 
with the agar dilution method according to the recommendation of Clinical and Laboratory 
Standard Institute (CLSI) [10]. Steers-Foltz’s replicator was used to place 105 CFU per spot 
onthe surface of Brucella agar supplemented with 5% laked sheep blood containing the 
antibiotics [10]. The following concentrations of the antibiotics were tested: ampicillin (2-256 
mg/l), amoxicillin/calvulanic acid (0.064-16 mg/l), cefoxitin (0.5-256 mg/l), meropenem 
(0.064-16 mg/l), clindamycin (0.064-256 mg/l), metronidazole (0.064-8 mg/l), moxifloxacin 
(0.064-32 mg/l), tetracycline (0.125-256 mg/l), tigecycline (0.064-32 mg/l), chloramphenicol 
(0.125-32 mg/l). We used fixed concentration of amoxicillin/clavulanic acid for stock 
solution (10/2.5 mg/ml). After 48 h incubation at 37 °C in an anaerobic chamber (Perkin 
Elmer, UK) under anaerobic conditions (85% N2, 10% CO2, 5% H2), the ampicillin, 
amoxcillin/clavulanic acid, meropenem, clindamycin, metronidazole MIC values were 
evaluated based on  breakpoints of the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST); however, cefoxitin, tetracycline, moxifloxacin and chloramphenicol 
were evaluated by the breakpoints of CLSI (Table 1) [10,11]. As neither EUCAST nor CLSI 
provided MIC values of tigecycline, we interpreted these MICs according to the data of the 
study published by Nagy et al. [4]. B. fragilis ATCC 25285 and B. thetaiotaomicron ATCC 
29741 were applied as control strains. Among the 400 strains, we found six MDR isolates. 
The clinical data of patients, who were infected by MDR Bacteroides isolates and their MIC 
values, are summarized in Table 2.3. RT-PCR 
 
Molecular investigations of the MDR isolates were carried out in order to detect  most 
common antibiotic resistance genes (cepA, cfxA, cfiA, nim, ermB, ermF, ermG, tetQ, tetX, 
tetX1, bexA), IS4351, the upstream region of cfiA and cfxA genes. In the case of gyrA, gyrB, 
parC and parE genes we looked for amino acid substitutions. DNA templates then were 
prepared by using the colony boiling lysis method. RT-PCR reactions were performed to 
detect cepA, cfxA, cfiA, ermF, ermB, ermG, tetQ, tetX, tetX1, bexA, gyrA genes and IS4351; 
while the end-point PCR method were used for the amplification of the upstream region of 
cfiA, cfxA genes and IS4351. The PCR products were analysed with 1.2% agarose gel 
electrophoresis; and the whole PCR set-up is summarised in Table 2. Positive controls used 
were the following: B. fragilis 638R (cepA), B. vulgatus CLA341 (cfxA, tetQ), B. fragilis 
638R (nim), B. fragilis (ermF), B. thetaiotaomicron (ermG), B. fragilis BM13 (tetX1), B. 
fragilis pBRT21 (bexA) [12]. 
2.4. Sequencing of the gyrA gene 
 
The DNA amplicon of the SZ38 B. fragilis strain (proportional scale-up to 30 μl) was 
purified using the Gel/PCR DNA Fragment Extraction Kit (Geneaid Biotech Ltd., Taiwan). 
And the PCR products were sequenced with ABI BigDye® Terminator Version 3.1 kit in the 
Series Genome Analyser 3500 (Life Technologies). 
 
3 Results 
 
A multicentre national survey was performed with 400 Bacteroides strains and six 
MDR isolates were found: one B. fragilis, two B. ovatus, two B. vulgatus and one B. 
thetaiotaomicron. As for the geographical distribution, one MDR strain was isolated from 
Debrecen (B. ovatus D92) and five from Szeged (B. vulgatus SZ4, SZ34 B. ovatus SZ9, B. 
thetaiotaomicron SZ35 and B. fragilis SZ38) were found, but none from the other centres 
(Table 1). Most of the MDR isolates in question displayed resistance to ampicillin (n=6), 
cefoxitin (n=4), moxifloxacin (n=5), clindamycin (n=4) and tetracycline (n=5), with a range 
of resistance from four to six different antibiotic classes. The results of the genetic analysis 
are summarised in Table 3. The B. fragilis SZ38 isolate harboured the cfiA gene with a high 
level resistance to ampicillin, amixicillin/calvulanic acid, cefoxitin, meropenem, but without 
any IS-element in the upstream region. None of the strains harboured the cepA gene, and 
three cfxA positive isolates (B. vulgatus SZ4, B. ovatus SZ9 and B. thetaiotaomicron SZ35) 
were detected. The 1.2 kb regulator region of the cfxA gene of the B. vulgatus SZ4 isolate was 
found. Four strains (B. ovatus D92, SZ9, B. vulgatus SZ34, and B. thetaiotamicron SZ35) 
expressed a high level of clindamycin resistance (MIC>256 mg/l), B. ovatus D92 harboured 
theermG gene, while B. vulgatus SZ4, B. thetaiotaomicron SZ35 ermF gene,and B. ovatus 
SZ9 contained both of them. The full length of IS4351 was detected in B. vulgatus SZ4 and 
B. thetaiotaomicron SZ35 strains, but we did not observe any physical association of these 
IS-s with ermF genes using PCR mapping. All of the isolates harboured the tetQ gene and 
three of them (B. ovatus D92, SZ9 and B. fragilis SZ38) expressed a high level tetracycline 
resistance (MIC>32 mg/l); moreover, the B. ovatus SZ9, B. vulgatus SZ34 and B. 
thetaiotaomicron SZ35 strains contained the tetX gene simultaneously. None of the isolates 
harboured the nim gene, but the B. ovatus D92 strain was metronidazole resistant based on 
the EUCAST breakpoints. The fluoroquinolone susceptibility test was performed with the 
measurement of moxifloxacin MIC-values. In the case of four strains, moxifloxacin MICs?32 
mg/l were detected, and among them the B. thetaiotamicron SZ35 harboured the bexA gene. 
Point mutations were investigated in the case of the gyrA gene of the B. fragilis SZ38 strain, 
and with a sequence analysis Ser82?Phe substitution in the QRDR region of the GyrA subunit 
of gyrase enzyme was detected. Tigecycline and chloramphenicol are very active against 
these isolates, both of them being susceptible to these two drugs.  
4 Discussion 
 
To date, MDR Bacteroides isolates have been rarely published. In the past decade, 
cases involving three Americans [13,14], one Briton [15], two Greeks [16], and one Japanese 
[17] have been published in the literature and one article published an investigation of five 
Danish isolates [6]. The case of an American soldier was also published, who suffered serious 
injuries in Afghanistan [18]. In our comprehensive, multicentre study we found six MDR 
isolates of 400 Bacteroides strains, which showed resistance to four to six different antibiotic 
groups. The molecular background of the resistance pattern of the MDR isolates differ from 
strain to strain. In Hungary, only one  MDR B. fragilis isolate has been published so far, 
which was resistant to penicillin, amoxicillin/clavulanic acid, piperacillin/tazobactam, 
cefoxitin, meropenem, clindamycin and tetracycline, harboured cepA, cfiA, erm, nimA, tetQ 
genes and IS1187 element [19]. The antibiotic resistance pattern, as well as the molecular 
background of the MDR Bacteroides isolates differ based on geographic location, type of 
isolate, species and antibiotic usage [19]. In the upstream region of the cfxA gene, special 
genetic elements (IS614B, Tn4555 and Tn4351) can be usually detected, (which were 
described earlier by Garcia et al. and Sóki et al. [20,21], but B. ovatus SZ9 and B. 
thetaiotamicron SZ35 harboured another IS-element or deletion. A Danish study reported 
five MDR B. fragilis blood culture isolates that harboured cfiA, nimA, nimD, nimE, nimJ, 
tetQ, ermB, ermF, LinA2 (clindamycin resistance), cepA, cfxA, bexB genes and different IS 
elements (IS614B, IS613B, IS1169, IS1187, IS1188, IS4351, ISBf6, ISBf12, ISBf13) [6]. B. 
fragilis SZ38 strain harboured cfiA gene, without any IS-element in the upstream region. 
None of our strains harboured the cepA gene, and three cfxA positive isolates were detected. 
Four strains harboured the ermG, ermF gene or both of them. The full length of IS4351 was 
detected in B. vulgatus SZ4 and B. thetaiotaomicron SZ35 strains. All of the isolates 
harboured the tetQ gene; moreover, the three strains contained the tetX gene simultaneously. 
Two strains harboured bexA gene; and none of them the nim gene. Ser82Phe substitution was 
found in GyrA region of the B. fragilis SZ38 strain, as well as Nakamura et al. reported in the 
case of MDR B. fragilis isolate [17].  
 
5 Conclusions 
 
The novelty of this study is that we demonstrated a relatively significant prevalence of 
MDR strains isolated in Szeged with five isolates and another strain from Debrecen. In the 
Central Eastern European region, up till now no similar study has reported such a large 
number of MDR Bacteroides strains. Almost all of them were resistant to ampicillin, 
cefoxitin, clindamycin, moxifloxacin and tetracycline, and harboured resistance genes and/or 
genetic elements related to the antibiotic resistance, according to the detailed molecular 
investigation. The background of the increasing number of MDR strains in the Szeged region 
may be the local habit of antibiotic usage, which might have led to an elevated level of 
resistance to several different antibiotics. This study demonstrates the importance of 
antimicrobial susceptibility testing and surveillance among B. fragilis group isolates. The 
increasing antibiotic resistance may be responsible for therapeutic failure and the higher 
mortality rate.  
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Table 1  Data of the MDR Bacteroides species strains 
Isolate 
Pure or 
mixed 
culture 
Age & 
gender 
Clinical 
presentation 
Sample 
type 
Department 
of isolation 
MIC values (mg/l) Treatment Outcome 
 
 
 
   
AMP 
(>2a) 
AUG 
(>8a) 
FOX 
(≥64b) 
MER 
(>8a) 
CLI 
(>4a) 
MTZ 
(>4a) 
MOX 
(≥8) 
TET 
(≥16b) 
TIG 
ND 
CHL 
(≥32b) 
  
D92                        
B. ovatus 
m 68 M 
Diabetes 
mellitus, 
atherosclerosis, 
renal failure,   
leg amputation 
Decubitus 
Internal 
medicine 
>256 >16 32 1 >256 >8 32 32 4 8 
Meropenem, 
clindamycin, 
vancomycin,  
colistin 
Alive 
SZ4                        
B. vulgatus 
m 64 M Diabetic foot Wound Surgery >256 >16 128 4 1 0,25 >32 16 0,25 4 
Ciprofloxacin 
Metronidazole 
Deceased 
SZ9                        
B. ovatus 
m 73 F Appendicitis 
Intraabdo-
minal fluid 
Surgery >256 16 32 16 >256 0,5 32 32 0,5 8 
Cefuroxime+M
etronidazole 
Ciprofolxacin+
Metronidazole 
Alive 
SZ34                      
B. vulgatus 
m 63 M 
C. difficile 
colitis 
Autopsy Pathology >256 >16 128 4 >256 0,5 32 8 0,125 4 ND Deceased 
SZ35                     
B. thetiotaomicron 
m 67 F Abrasion 
Intrauterine 
device 
Obstetrics & 
Gynecology 
>256 16 128 2 >256 0,5 1 16 0,25 8 
No antibiotic 
treatment 
Alive 
SZ38                      
B. fragilis 
m 76 M 
Diabetic foot, 
atherosclerosis, 
leg amputuation 
Wound Surgery >256 >16 128 16 8 0,5 8 32 0,5 4 Meropenem Deceased 
 
AMP: Ampicillin, AMC: Amoxicillin/clavulanic acid, FOX: Cefoxitin, MER: Meropenem, CLI: Clindamycin,                                                                                                                MZT: 
Metronidazole, MOX: Moxifloxacin, TET: Tetracycline, TIG: Tigecycline, CHO: Chloramphenicol 
m: mixed culture     M: male     F: female    a EUCAST breakpoints    b CLSI breakpoints    ND: No data 
Table 2 PCR reaction parameters of the  genes and genetic elements examined 
Gene Primers (5’ → 3’) PCR cycles 
cfiA AATCGAAGGATGGGGTATGG 95 °C 15 s, 59 °C 30 s, 72 °C 30s, 35x 
 CGGTCAGTGAATCGGTGAAT  
cfxA TGACTGGCCCTGAATAATCT 95 °C 15 s, 55 °C 30 s, 72 °C 30s, 35x 
 ACAAAAGATAGCGCAAATCC  
cepA TTTCTGCTATGTCCTGCCT 95 °C 15 s, 56 °C 30 s, 72 °C 1 min, 35x 
 ATCTTTCACGAAGACGGC  
nim ATGTTCAGAGAAATGCGGCGTAAGTG 94 °C 15 s, 62 °C 30 s, 72  °C 30 s, 35x 
 GCTTCCTCGCCTGTCACGTGCTC  
ermF TAGATATTGGGGCAGGCAAG 95 °C 15 s, 58 °C 1 min, 72 °C 30 s, 35x 
 GGAAATTGCGGAACTGCAAA  
ermB GCGGAATGCTTTCATCCTAA 95 °C 15 s, 59 °C 30 s, 72 °C 30 s, 35x 
 GCGTGTTTCATTGCTTGATG  
ermG ATAGGTGCAGGGAAAGGTCA 95 °C 15 s, 59 °C 30 s, 72 °C 30 s, 35x 
 TGGATTGTGGCTAGGAAATGT  
tetQ ATCGGTATCAATGAGTTGTT 95 °C 15 s, 50 °C 1 min, 72 °C 30 s, 35x 
 GACTGATTCTGGAGGAAGTA  
tetX TTAGCCTTACCAATGGGTGT 95 °C 15 s, 55 °C 30 s, 72 °C 30 s, 35x 
 CAAATCTGCTGTTTCATTCG  
tetX1 TCAGGACAAGAAGCAATGAA 95 °C 15 s, 50 °C 1 min, 72 °C 30 s, 32x 
 TATTTCGGGGTTGTCAAACT  
bexA TAGTGGTTGCTGCGATTCTG 95 °C 15 s, 60 °C 30 s, 72 °C 30 s, 35x 
 TCAGCGTCTTGGTCTGTGTC  
IS4351 CAGGGTCTGGATACGCAAGT 95 °C 15 s, 59 °C 30 s, 72 °C 30 s, 35x 
 CTGATAAGCCCGTTGGTGTT  
gyrA CTACGGAATGATGGAACTGG 95 °C 15 s, 53 °C 30 s, 72 °C 30 s, 35x 
 TGTTCAGACGTGCTTCAGTG  
 
Table 3. RT-PCR results of the MDR Bacteroides species strains 
Strains cfiA 
cfiA 
IS 
cepA cfxA 
cfxA 
upstream 
nim ermF 
ermF 
IS 
IS4351 ermB ermG tetQ tetX tetX1 bexA gyrA 
D92 - N. A.* - - N. A. - - N. A. - - + + - - - N. A. 
SZ4 - N. A. - + 1.2 kb** - - N. A. + - - + - - - N. A. 
SZ9 - N. A. - + D/IS*** - + N. A. - - + + + - + N. A. 
SZ34 - N. A. - - N. A. - + N. A. - - - + + - - N. A. 
SZ35 - N. A. - + D/IS - + - + - - + + - + N. A. 
SZ38 + 282 bp - - N. A. - - N. A. - - - + - - - 82Ser→Phe 
                 
 
*N. A.: not applicable     **1.2 kb  regulator region       ***D/IS.: deletion or otherIS-element 
 
 
